These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
448 related items for PubMed ID: 8636336
1. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. de Boer H, Blok GJ, Popp-Snijders C, Stuurman L, Baxter RC, van der Veen E. J Clin Endocrinol Metab; 1996 Apr; 81(4):1371-7. PubMed ID: 8636336 [Abstract] [Full Text] [Related]
2. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency. Thorén M, Hilding A, Baxter RC, Degerblad M, Wivall-Helleryd IL, Hall K. J Clin Endocrinol Metab; 1997 Jan; 82(1):223-8. PubMed ID: 8989263 [Abstract] [Full Text] [Related]
3. The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group. Dall R, Longobardi S, Ehrnborg C, Keay N, Rosén T, Jørgensen JO, Cuneo RC, Boroujerdi MA, Cittadini A, Napoli R, Christiansen JS, Bengtsson BA, Sacca L, Baxter RC, Basset EE, Sönksen PH. J Clin Endocrinol Metab; 2000 Nov; 85(11):4193-200. PubMed ID: 11095453 [Abstract] [Full Text] [Related]
4. A low starting dose of genotropin in growth hormone-deficient adults. Janssen YJ, Frölich M, Roelfsema F. J Clin Endocrinol Metab; 1997 Jan; 82(1):129-35. PubMed ID: 8989246 [Abstract] [Full Text] [Related]
5. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. Marzullo P, Di Somma C, Pratt KL, Khosravi J, Diamandis A, Lombardi G, Colao A, Rosenfeld RG. J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159 [Abstract] [Full Text] [Related]
6. The optimal growth hormone replacement dose in adults, derived from bioimpedance analysis. de Boer H, Blok GJ, Voerman B, de Vries P, Popp-Snijders C, van der Veen E. J Clin Endocrinol Metab; 1995 Jul; 80(7):2069-76. PubMed ID: 7608257 [Abstract] [Full Text] [Related]
12. Effect of severe growth hormone (GH) deficiency due to a mutation in the GH-releasing hormone receptor on insulin-like growth factors (IGFs), IGF-binding proteins, and ternary complex formation throughout life. Aguiar-Oliveira MH, Gill MS, de A Barretto ES, Alcântara MR, Miraki-Moud F, Menezes CA, Souza AH, Martinelli CE, Pereira FA, Salvatori R, Levine MA, Shalet SM, Camacho-Hubner C, Clayton PE. J Clin Endocrinol Metab; 1999 Nov; 84(11):4118-26. PubMed ID: 10566659 [Abstract] [Full Text] [Related]
13. Double blind trial comparing the effects of two doses of growth hormone in prepubertal patients with chronic renal insufficiency. Hokken-Koelega AC, Stijnen T, De Jong MC, Donckerwolcke RA, De Muinck Keizer-Schrama SM, Blum WF, Drop SL. J Clin Endocrinol Metab; 1994 Oct; 79(4):1185-90. PubMed ID: 7525628 [Abstract] [Full Text] [Related]
14. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy. Thorén M, Hilding A, Brismar T, Magnusson P, Degerblad M, Larsson L, Sääf M, Baylink DJ, Mohan S. J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754 [Abstract] [Full Text] [Related]
15. Growth hormone (GH) provocative retesting of 108 young adults with childhood-onset GH deficiency and the diagnostic value of insulin-like growth factor I (IGF-I) and IGF-binding protein-3. Juul A, Kastrup KW, Pedersen SA, Skakkebaek NE. J Clin Endocrinol Metab; 1997 Apr; 82(4):1195-201. PubMed ID: 9100596 [Abstract] [Full Text] [Related]
16. Administration of growth hormone (GH), but not insulin-like growth factor-I (IGF-I), by continuous infusion can induce the formation of the 150-kilodalton IGF-binding protein-3 complex in GH-deficient rats. Gargosky SE, Tapanainen P, Rosenfeld RG. Endocrinology; 1994 May; 134(5):2267-76. PubMed ID: 7512499 [Abstract] [Full Text] [Related]
17. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3. Arosio M, Garrone S, Bruzzi P, Faglia G, Minuto F, Barreca A. J Clin Endocrinol Metab; 2001 Mar; 86(3):1091-8. PubMed ID: 11238491 [Abstract] [Full Text] [Related]
18. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database). Popovic V, Mattsson AF, Gaillard RC, Wilton P, Koltowska-Häggström M, Ranke MB. J Clin Endocrinol Metab; 2010 Sep; 95(9):4449-54. PubMed ID: 20610598 [Abstract] [Full Text] [Related]
19. Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement. Span JP, Pieters GF, Sweep CG, Hermus AR, Smals AG. J Clin Endocrinol Metab; 2000 Mar; 85(3):1121-5. PubMed ID: 10720049 [Abstract] [Full Text] [Related]
20. Characterization of a low molecular mass form of insulin-like growth factor binding protein-3 (17.7 kilodaltons) in urine and serum from healthy children and growth hormone (GH)-deficient patients: relationship with GH therapy. Spagnoli A, Gargosky SE, Spadoni GL, MacGillivray M, Oh Y, Boscherini B, Rosenfeld RG. J Clin Endocrinol Metab; 1995 Dec; 80(12):3668-76. PubMed ID: 8530618 [Abstract] [Full Text] [Related] Page: [Next] [New Search]